The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116).
 
Ezra Rosen
No Relationships to Disclose
 
Ian M. Silverman
Employment - Repare Therapeutics
Stock and Other Ownership Interests - Repare Therapeutics
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Consulting or Advisory Role - Astellas Pharma (I); Bristol-Myers Squibb (I); Celgene (I); SERVIER (I)
Patents, Royalties, Other Intellectual Property - Patent No: 1716712.3 pending (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); SERVIER (I)
 
Elizabeth Katherine Lee
Research Funding - Repare Therapeutics (Inst); Seagen (Inst)
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curio Science (Inst); EMD Serono (Inst); Evidera (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intellisphere (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Molecular Templates (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Martin Højgaard
Stock and Other Ownership Interests - Bavarian Nordic; Illumina; Pacific Biosciences
Consulting or Advisory Role - LingoMedical
Research Funding - Amgen; Incyte; Repare Therapeutics
Travel, Accommodations, Expenses - Roche
Other Relationship - Danish Medicines Council
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Novartis; Novartis; Novocure; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Niharika B. Mettu
Research Funding - Amgen (Inst); Amphivena (Inst); ARMO BioSciences/Lilly; AstraZeneca/MedImmune; BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); ERYTECH Pharma; Genentech (Inst); Incyte (Inst); Lucence Diagnostics (Inst); Merck; Mereo BioPharma; OncoMed; Repare Therapeutics (Inst); Revolution Medicines; Syros Pharmaceuticals
 
Benedito A. Carneiro
Consulting or Advisory Role - Eisai; Foundation Medicine; G1 therapeutics; Seagen; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Dragonfly Therapeutics (Inst); Pfizer (Inst); Repare Therapeutics (Inst)
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics; Boehringer Ingelheim
Research Funding - Athenex (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Repare Therapeutics (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Athenex; BerGenBio; BerGenBio
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Novartis; Onxeo; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Joseph D. Schonhoft
Employment - Repare Therapeutics
Stock and Other Ownership Interests - Epic Sciences; Repare Therapeutics
Consulting or Advisory Role - Epic Sciences
 
Danielle Ulanet
Employment - Repare Therapeutics
Stock and Other Ownership Interests - Repare Therapeutics
 
Peter Manley
Employment - Repare Therapeutics
 
Jorge S. Reis-Filho
Leadership - Grupo Oncoclinicas
Stock and Other Ownership Interests - PAIGE.AI; Repare Therapeutics
Consulting or Advisory Role - Genentech/Roche; Goldman Sachs; Invicro; Lilly; Novartis; Paige.AI; Personalis; Repare Therapeutics; Ventana Medical Systems; Volition RX
 
Yi Xu
Employment - Repare Therapeutics
Stock and Other Ownership Interests - Repare Therapeutics
 
Victoria Rimkunas
Employment - Repare Therapeutics
Stock and Other Ownership Interests - Repare Therapeutics
Research Funding - Invitae (Inst); MSK Pharma (Inst)
 
Maria Koehler
Employment - Bicycle Therapeutics; Repare Therapeutics
Stock and Other Ownership Interests - Ikena Oncology; Pfizer; Repare Therapeutics; Silverback Therapeutics
Honoraria - Atheneum; Gerson Lehrman Group
 
Timothy A. Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Clovis Oncology; Cybrexa Therapeutics; Diffusion Pharmaceuticals; EMD Serono; F-Star; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; Idience; Ignyta; ImmuneSensor Therapeutics; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Natera; Nexys Therapeutics; Novocure; OncoSec; Ono Pharmaceutical; Oregon Health & Science University (OHSU); Pegascy; PER; Pfizer; Piper Sandler; ProLynx; Repare Therapeutics; resTORbio; Roche; Schrodinger; Theragnostics; Varian Medical Systems; Versant Health; Vibliome Therapeutics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); ImmuneSensor Therapeutics (Inst); Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vivace Therapeutics (Inst); Zenith (Inst)